Skip to content

Released Nov 9, 2022, before the open

10-Q filed Nov 9, 2022, 40 days after period end · 0001171843-22-007269

Q3 2022 · 10-Q
Revenue—
Net Income-$11.98MN/M vs Q3 2021N/M vs Q2 2022
EPS, diluted—
Operating Income-$12,598,000N/M
Operating Cash Flowderived-$10,942,000N/M
Free Cash Flowderived-$10,969,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Net Income-$11.98M-$5.98M-$9.15M-$8.55M
EPS Diluted—-$0.10-$0.18-$1.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR